THE SIGNIFICANT COST FOR A BRAND-NEW MUSCULAR DYSTROPHY MEDICINE IS GENERATING RAGE. THEY ARE POSTPONING THE LAUNCH AFTER PUBLIC OUTRAGE AND ALSO WASHINGTON LEGISLATORS OBTAINED INVOLVED. CBS 2'' S DR. MAX GOMEZ WITH THE DISPUTE. THAT'' S RIGHT, PEOPLE. THE DEFLAZACORT IS NOT A REMEDY BUT IT DOES SLOW THE PROGRESSION OF MUSCULAR DYSTROPHY. IT'' S BEEN AVAILABLE IN EUROPE AS WELL AS ASIA FOR YEARS BUT NOT IN THE U.S. AFTER THAT THE FDA APPROVED IT ORPHAN MEDICATION STANDINGS AND AFTERWARDS AMERICAN COMPANY OBTAINED AUTHORIZATION RECENTLY BUT WHAT SHOULD HAVE BEEN GOOD INFORMATION SWIFTLY GOT ANGRY. DYLAN NELSON HAS A RARE KIND OF MUSCULAR DYSTROPHY CALLED DUCHENNE FOUND ALMOST EXCLUSIVELY IN BOYS.THE DEADLY CONGENITAL DISEASE DETERIORATES HIS MUSCLE MASS IN TIME BUT ALSO FOR THE PAST TEN YEARS, THE STEROID DEFLAZACORT HAS HELPED. THIS IS A MEDICATION THAT ADDS LIKELY THREE YEARS OF STROLLING FOR CHILDREN. SO IN ALL PROBABILITY DYLAN ENTERED INTO A MOBILITY DEVICE LATER THREE YEARS THAN HE WOULD HAVE. Press reporter: RESEARCHERS AT UCLA RESEARCHING DUCHENNE. PREVIOUSLY INDIVIDUALS HAD TO FIND A METHOD TO GET THE DRUG FROM OVERSEAS. THE FDA-APPROVED THE DRUG AVAILABLE IN THIS COUNTRY RECENTLY AND ALSO MARATHON PHARMACEUTICALS WAS ABOUT TO BEGINNING MARKETING IT UNTIL THE COMPANY STATED IT WOULD CHARGE $89,000 A YEAR FOR DEFLAZACORT COMPARED TO SIMPLY $1,200 FOR THE GENERIC VERSION ABROAD. THE PRICE HAS OUTRAGED LAWMAKERS ON CAPITOL HILLSIDE THAT WILL CERTAINLY PUT STRESS ON MARATHON. MEDICINE FIRMS CAN COST United States ANY RATE THEM. THAT'' S WHY WE HAVE THE HIGHEST POSSIBLE AROUND THE WORLD PRICES FOR MEDICINE. Reporter: THE FEDERAL GOVERNMENT HAS NO OVERSIGHT IN RATES BUT BERNIE SANDERS IS CALLING FOR AN INVESTIGATION.WE ARE GOING TO BE THEIR WORST NIGHTMARE. Reporter: WE WANT TO DECIDE THAT BRINGS THE BENEFIT OF THIS MEDICATION TO ALL CLIENTS WHO NEED IT DESPITE THEIR CAPABILITY TO PAY AND ALSO ENABLES TO US CONTINUE FURTHER STUDY, THEY SAID. MARATHON DID NOT SAY EXACTLY WHY IT HAD ACTUALLY POSTPONED LAUNCH OF THE DRUG BUT CLAIMED THAT CO-PAYS FOR CLIENTS WOULD BE ABSOLUTELY NO OR VERY LOW. NATURALLY THAT IMPLIES INSURANCE PROVIDER WOULD BE FOOTING THE BILL FOR THE MEDICATION, AS WELL AS THOSE PRICES WOULD BE BORNE BY ALL OF US.
